Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03859050 · ClinicalTrials.gov registry record · NA
Alveolar Macrophage Programming Following Endotoxin Exposure
A NA study of ARDS, Human, sponsored by National Jewish Health.
- Recruiting
- Registry status
- NA
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT03859050: Recruiting NA study of ARDS, Human, sponsored by National Jewish Health.
NCT03859050 is a NA study of ARDS, Human that is actively recruiting participants, run by National Jewish Health. The registered enrollment target is 25 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03859050, a NA study of ARDS, Human, is actively recruiting participants, sponsored by National Jewish Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for alveolar repair to occur inflammation must be halted, debris and inflammatory cells removed, injured tissue cells replaced, and capillary barrier function re-established. Macrophages are key players in all of these. Here the investigators hypothesize that resident alveolar macrophages and recruited macrophages serve completely different functions, acting independently (i.e. division of labor) yet cooperatively (synergism).
Primary Outcome
Resident and recruited macrophages will be purified using fluorescence activated cell sorting (FACS) and subjected to RNA sequencing.
Conditions Studied
Interventions
- OTHER bronchoscopy with intrabronchial administration of lipopolysaccharide
Study Locations (1)
Colorado
- National Jewish Health - Denver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-03-18 |
| Est. Completion | 2032-07 |
| Phase | NA |
What NCT03859050 shows while recruiting
NCT03859050 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with ARDS, Human appearing as the primary indexed condition, and to 1 intervention - of which bronchoscopy with intrabronchial administration of lipopolysaccharide is the first listed.
NCT03859050 reports a single indexed study location in Colorado.
Frequently Asked Questions
What is clinical trial NCT03859050 about?
NCT03859050 is a clinical study titled "Alveolar Macrophage Programming Following Endotoxin Exposure". The histologic hallmarks of lung inflammation include accumulation of inflammatory cells in the airspaces and interstitium, injury to alveolar epithelial and endothelial cells, loss of epithelial-capillary integrity and accumulation of edema fluid in the interstitium and airspaces. Accordingly, for ...
What is the current status of trial NCT03859050?
This trial is currently recruiting. It is a NA study. The enrollment target is 25 participants. The study started on 2019-03-18. Estimated completion is 2032-07.
What conditions does trial NCT03859050 study?
This clinical trial studies the following conditions: ARDS, Human.
What interventions are being tested in trial NCT03859050?
The interventions under investigation include: bronchoscopy with intrabronchial administration of lipopolysaccharide (OTHER).
Who is sponsoring clinical trial NCT03859050?
This trial is sponsored by National Jewish Health, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03859050 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ARDS, Human
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03859050's enrollment target sits among peer trials
25 1713th of 2000 higher than 265 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI